vs
Esperion Therapeutics, Inc.（ESPR）与FIRST MERCHANTS CORP（FRME）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是FIRST MERCHANTS CORP的1.1倍（$168.4M vs $157.1M），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -0.9%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
第一商人集团是总部位于美国印第安纳州曼西的金融控股公司，业务覆盖印第安纳州中部地区，旗下拥有第一商人银行、第一商人私人财富顾问两大板块，在纳斯达克上市，股票代码为FRME。截至2023年3月，集团总资产达182亿美元，为客户提供商业银行、个人银行及投资顾问服务。
ESPR vs FRME — 直观对比
营收规模更大
ESPR
是对方的1.1倍
$157.1M
两年增速更快
ESPR
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $157.1M |
| 净利润 | — | $28.2M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | 17.9% |
| 营收同比 | 143.7% | — |
| 净利润同比 | — | -49.1% |
| 每股收益（稀释后） | $0.32 | $0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRFRME
| Q1 26 | — | $157.1M | ||
| Q4 25 | $168.4M | $172.2M | ||
| Q3 25 | $87.3M | $166.1M | ||
| Q2 25 | $82.4M | $164.3M | ||
| Q1 25 | $65.0M | $160.3M | ||
| Q4 24 | $69.1M | $177.1M | ||
| Q3 24 | $51.6M | $156.0M | ||
| Q2 24 | $73.8M | $159.9M |
净利润ESPRFRME
| Q1 26 | — | $28.2M | ||
| Q4 25 | — | $57.1M | ||
| Q3 25 | $-31.3M | $56.8M | ||
| Q2 25 | $-12.7M | $56.8M | ||
| Q1 25 | $-40.5M | $55.3M | ||
| Q4 24 | — | $64.3M | ||
| Q3 24 | $-29.5M | $49.2M | ||
| Q2 24 | $-61.9M | $39.9M |
营业利润率ESPRFRME
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 38.0% | ||
| Q3 25 | -11.4% | 39.3% | ||
| Q2 25 | 8.6% | 39.6% | ||
| Q1 25 | -34.0% | 39.4% | ||
| Q4 24 | -6.4% | 43.3% | ||
| Q3 24 | -31.0% | 36.1% | ||
| Q2 24 | 3.5% | 27.5% |
净利率ESPRFRME
| Q1 26 | — | 17.9% | ||
| Q4 25 | — | 33.1% | ||
| Q3 25 | -35.9% | 34.2% | ||
| Q2 25 | -15.4% | 34.6% | ||
| Q1 25 | -62.2% | 34.5% | ||
| Q4 24 | — | 36.3% | ||
| Q3 24 | -57.2% | 31.5% | ||
| Q2 24 | -83.9% | 25.0% |
每股收益（稀释后）ESPRFRME
| Q1 26 | — | $0.45 | ||
| Q4 25 | $0.32 | $0.98 | ||
| Q3 25 | $-0.16 | $0.98 | ||
| Q2 25 | $-0.06 | $0.98 | ||
| Q1 25 | $-0.21 | $0.94 | ||
| Q4 24 | $-0.14 | $1.09 | ||
| Q3 24 | $-0.15 | $0.84 | ||
| Q2 24 | $-0.33 | $0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $2.7B |
| 总资产 | $465.9M | $21.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRFRME
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
股东权益ESPRFRME
| Q1 26 | — | $2.7B | ||
| Q4 25 | $-302.0M | $2.5B | ||
| Q3 25 | $-451.4M | $2.4B | ||
| Q2 25 | $-433.5M | $2.3B | ||
| Q1 25 | $-426.2M | $2.3B | ||
| Q4 24 | $-388.7M | $2.3B | ||
| Q3 24 | $-370.2M | $2.3B | ||
| Q2 24 | $-344.2M | $2.2B |
总资产ESPRFRME
| Q1 26 | — | $21.1B | ||
| Q4 25 | $465.9M | $19.0B | ||
| Q3 25 | $364.0M | $18.8B | ||
| Q2 25 | $347.1M | $18.6B | ||
| Q1 25 | $324.0M | $18.4B | ||
| Q4 24 | $343.8M | $18.3B | ||
| Q3 24 | $314.1M | $18.3B | ||
| Q2 24 | $352.3M | $18.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRFRME
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $283.6M | ||
| Q3 25 | $-4.3M | $87.6M | ||
| Q2 25 | $-31.4M | $53.7M | ||
| Q1 25 | $-22.6M | $61.7M | ||
| Q4 24 | $-35.0M | $266.2M | ||
| Q3 24 | $-35.3M | $76.8M | ||
| Q2 24 | $-7.2M | $63.0M |
自由现金流ESPRFRME
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
自由现金流率ESPRFRME
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
资本支出强度ESPRFRME
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
现金转化率ESPRFRME
| Q1 26 | — | — | ||
| Q4 25 | — | 4.97× | ||
| Q3 25 | — | 1.54× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | — | 1.58× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FRME
| Net Interest Income | $151.3M | 96% |
| Noninterest Income | $5.8M | 4% |
